Palisade Bio Inc

NASDAQ:PALI   3:59:45 PM EDT
0.52
+0.01 (+2.95%)
Products

Palisade Bio Receives FDA “Study May Proceed” Letter For Pivotal Phase 3 Clinical Trial Evaluating LB1148 To Accelerate Return Of Bowel Function Following Abdominal Surgery

Published: 03/22/2022 13:33 GMT
Palisade Bio Inc (PALI) - Palisade Bio (nasdaq: Pali) Receives FDA “study May Proceed” Letter for Pivotal Phase 3 Clinical Trial Evaluating Lb1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery.
Palisade Bio - Receives FDA "study May Proceed" Letter for Phase 3 Clinical Trial Evaluating Lb1148 to Accelerate Return of Bowel Function After Abdominal Surgery.